Ciprofloxacin for treatment of tularemia in children

Pediatric Infectious Disease Journal

Volumn 19, Issue 5, 2000, Pages 449-453

  Johansson, Anders ^a,b   Berglund, Lennart ^c   Gothefors, Leif ^a   Sjöstedt, Anders ^a,b   Tärnvik, Arne ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b SWEDISH DEFENCE RESEARCH AGENCY   (Sweden)

^c Primary Health Care Center   (Sweden)

Author keywords

Antibiotic susceptibility; Antibiotic treatment; Childhood; Ciprofloxacin; E test; Francisella tularensis; Tularemia

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CIPROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; FRANCISELLA TULARENSIS; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATIENT SATISFACTION; PRIORITY JOURNAL; RASH; TREATMENT OUTCOME; TULAREMIA;

EID: 0034075476     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200005000-00011     Document Type: Article

References (34)

1. Dienst FT. Tularemia: a perusal of three hundred thirty-nine cases. J La State Med Soc 1963;115:114-27.
2. Jellison WL. Tularemia in North America, 1929-1974. Missoula, MT: University of Montana, 1974.
3. McCrumb FR. Aerosol infection of man with Pasteurella tularensis. Bacteriol Rev 1961;25:262-7.
4. Syrjälä H, Kujala P, Myllylä V, Salminen A. Airborne transmission of tularemia in farmers. Scand J Infect Dis 1985;17: 371-5.
5. Enderlin G, Morales L, Jacobs RF, Cross JT. Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clin Infect Dis 1994;19:42-7.
6. Sawyer WD, Dangerfield HG, Hogge AL, Crozier D. Antibiotic prophylaxis and therapy of airborne tularemia. Bacteriol Rev 1966;30:542-50.
7. Penn RL. Francisella tularensis (tularemia). In: Mandell GL, Bennet JE, Dolin R, eds. Mandell, Douglas and Bennet's Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995:2060-8.
8. Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis 1997; 25:1196-204.
9. Schaad UB, Salam MA, Aujard Y, et al. Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission. Pediatr Infect Dis J 1995;14:1-9.
10. Scheel O, Hoel T, Sandvik T, Berdal BP. Susceptibility pattern of Scandinavian Francisella tularensis isolates with regard to oral and parenteral antimicrobial agents. APMIS 1993;101:33-6.
11. Syrjälä H, Schildt R, Raisainen S. In vitro susceptibility of Francisella tularensis to fluoroquinolones and treatment of tularemia with norfloxacin and ciprofloxacin. Eur J Clin Microbiol Infect Dis 1991;10:68-70.
12. Russell P, Eley SM, Fulop MJ, Bell DL, Titball RW. The efficacy of ciprofloxacin and doxycycline against experimental tularaemia. J Antimicrob Chemother 1998;41:461-5.
13. Scheel O, Reiersen R, Hoel T. Treatment of tularemia with ciprofloxacin. Eur J Clin Microbiol Infect Dis 1992;11:447-8.
14. Risi GF, Pombo DJ. Relapse of tularemia after aminoglycoside therapy: case report and discussion of therapeutic options. Clin Infect Dis 1995;20:174-5.
15. Sjöstedt A, Eriksson U, Berglund L, Tärnvik A. Detection of Francisella tularensis in ulcers of patients with tularemia by PCR. J Clin Microbiol 1997;35:1045-8.
16. Sandström G, Tärnvik A, Wolf-Watz H, Löfgren S. Antigen from Francisella tularensis: nonidentity between determinants participating in cell-mediated and humoral reactions. Infect Immun 1984;45:101-6.
17. SRGA Homepage (www.srga.org) Version 3. The Swedish Reference Group for Antibiotics (SRGA) and its subcommittee on methodology (SRGA-M) [Online] http://www.ltkrono-berg.se/ext/raf/raf.htm [December 12, 1999, last date accessed.].
18. Jacobs RF, Condrey YM, Yamauchi T. Tularemia in adults and children: a changing presentation. Pediatrics 1985;76: 818-22.
19. Markowitz LE, Hynes NA, de la Cruz P, et al. Tick-borne tularemia: an outbreak of lymphadenopathy in children. JAMA 1985;254:2922-5.
20. Syrjälä H, Herva E, Ilonen J, Saukkonen K, Salminen A. A whole-blood lymphocyte stimulation test for the diagnosis of human tularemia. J Infect Dis 1984;150:912-5.
21. Tärnvik A, Sandström G, Löfgren S. Time of lymphocyte response after onset of tularemia and after tularemia vaccination. J Clin Microbiol 1979;10:854-60.
22. Tärnvik A, Sandström G, Sjöstedt A. Infrequent manifestations of tularaemia in Sweden. Scand J Infect Dis 1997;29: 443-6.
23. Thornsberry C, Hill BC, Swenson JM, McDougal LK. Rifampin: spectrum of antibacterial activity. Rev Infect Dis 1983;5(Suppl 3):S412-7.
24. Jacobs RF, Narain JP. Tularemia in children. Pediatr Infect Dis 1983;2:487-91.
25. Uhari M, Syrjälä H, Salminen A. Tularemia in children caused by Francisella tularensis biovar palaearctica. Pediatr Infect Dis J 1990;9:80-3.
26. Bhatnagar N, Getachew E, Straley S, Williams J, Meltzer M, Fortier A. Reduced virulence of rifampicin-resistant mutants of Francisella tularensis. J Infect Dis 1994;170:841-7.
27. Cross JT, Jacobs RF. Tularemia: Treatment failures with outpatient use of ceftriaxone. Clin Infect Dis 1993;17:976-80.
28. Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 1997; 39:677-86.
29. Laureillard D, Paquet C, Malvy D. Ciprofloxacine dans le traitement de la dysenterie à Shigella dysenteriae de type 1 lors d'une épidémie chez les réfugiés rwandais à Goma en 1994. Santé 1998;8:303-5.
30. Salam MA, Dhar U, Khan WA, Bennish ML. Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis. Lancet 1998;352:522-7.
31. Green S, Tillotson G. Use of ciprofloxacin in developing countries. Pediatr Infect Dis J 1997;16:150-9.
32. Church DA, Kanga JF, Kuhn RJ, et al. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group. Pediatr Infect Dis J 1997;16:97-105.
33. Richard DA, Nousia-Arvanitakis S, Sollich V, Hampel BJ, Sommerauer B, Schaad UB. Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group. Pediatr Infect Dis J 1997;16:572-8.
34. Jick S. Ciprofloxacin safety in a pediatric population. Pediatr Infect Dis J 1997;16:130-3.